NEJM: Oral Relugolix For Advanced Prostate Cancer

The oxyperolin injection is the standard drug for prostate cancer, and researchers recently examined the efficacy of the oral gonadotropin-releasing hormone antagonist Relugolixpatients with advanced prostate cancer participated in this Phase III clinical study, were randomized to receive Elugolix (120 mg orally, once daily) or eryprotriline (every 3 months) for 48 weeks of treatmentThe main endpoint of the study was continuous testosterone suppression (defined as testosterone content of 50 ng/ml) for 48 weeksSecondary endpoints include non-effects associated with the main endpoint, testosterone levels after 4th day castration and post-deep castration levels (20 ng/ml) on the 15th dayTestosterone recovery was assessed in a subgroup of patientsa total of 622 patients received Relugolix treatment and 308 patients received the treatment of erythlinAmong men treated with Relugolix, 96.7 per cent continued testosterone-suppressing castration for 48 weeks, compared with 88.8 per cent of men treated with leprosy, a difference of 7.9 per centThe percentage of patients with testosterone suppression on the fourth day after treatment in the Relugolix group was 56.0% and the percentage of patients with oxypriate was 0%After 90 days of discontinuation, the average testosterone level in the Relugolix group was 288.4 ng/ml, and the lucline group was 58.6 ng/mlThe incidence of major cardiovascular adverse events was 2.9% in the Relugolix group and 6.2% in the Lianglelin groupstudies suggest that in patients with advanced prostate cancer, Relugolix is able to suppress testosterone levels quickly and consistently, better than eryecrelin